Matteo Giovanni Della Porta is head of Leukemia Unit at Humanitas Cancer Center in Milan, where he is also the head of the Genomics of Hematological Neoplasms Lab. He is full professor of Hematology at Humanitas University and director of the Center for Acclelerating Leukemia/Lymphoma Research, a joint effort from Humanitas University, Humanitas Research Hospital, Humanitas AI Center and the Politecnico di Milano. He obtained his Medical Degree with honors at the University of Pavia Medical School, Italy in 1999. From 2000 to 2003 he completed his training in Hematology at the Department of
Abstract Selection of a hematopoietic progenitor cell donor for allogeneic hematopoietic cell transplantation (HCT) is essential for treatment planning; however, the parameters that define an “optimal” donor in the modern era are not well defined. Historically, donor-recipient…
Abstract Allogeneic stem cell transplantation (SCT) is a curative treatment in myelodysplastic syndromes (MDS). We performed a retrospective single center study of all patients with newly diagnosed higher risk (HR) MDS (IPSS-R > 3.5 points) between 2000 and 2023. We identified…
Abstract The diagnosis and treatment of hematologic malignancies has undergone significant advancements over the past few decades, resulting in enhanced outcomes. For hematologic malignancies diagnosed during pregnancy, this poses new questions. As possibilities continue to…
Abstract Venetoclax (Ven) in combination with hypomethylating agents (HMA) (azacitidine or decitabine) is the standard of care for elderly or unfit patients with acute myeloid leukemia (AML) and is being explored in high-risk myelodysplastic syndrome (HR-MDS). However, currently…
Abstract Allogeneic stem cell transplantation (SCT) is a curative treatment in myelodysplastic syndromes (MDS). We performed a retrospective single center study of all patients with newly diagnosed higher risk (HR) MDS (IPSS-R > 3.5 points) between 2000 and 2023. We identified…
Introduction: Paroxysmal nocturnal haemoglobinuria (PNH) is an uncommon, life-threatening disease, caused by intravascular haemolysis by the complement system
Patients at risk for progression from myeloid precursor states (ICUS, CCUS) to MDS are not well defined. Epidemiologic risk factors, clonal changes for MDS development, and evolution from one MDS state to another (lower- (LR) or higher-risk (HR) disease or leukemia [AML]) are available in the MDS NHS, a prospective cohort enrolled at diverse US sites. Extensive clinical data and biospecimens are collected at baseline and follow-up.
About 25% of patients with myelodysplastic syndromes myelodysplastic syndromes: